Back to Press Releases Health Canada Approves Animas IR 1200 Insulin Pump

Health Canada Approves Animas IR 1200 Insulin Pump for Distribution

West Chester, PA - September 14, 2004 - Animas Corporation (Nasdaq: PUMP), a leading manufacturer of insulin pumps, announced today that Health Canada has approved the distribution of the Animas IR 1200 insulin pump in Canada.

The IR 1200 pump received approval from the U.S. Food and Drug Administration in November 2003 and has been available in the U.S. since April 2004. The IR 1200 will be available in Canada this month and will be distributed by Auto Control Medical, Animas' exclusive Canadian distributor.

The IR 1200 is the smallest full feature pump on the market today, offering a large viewing screen, long battery life, precise insulin delivery, enhanced waterproof integrity and ease-of-use.

"We're very excited that our neighbors to the north can benefit from the smart technology, intuitive features and reliability of our latest generation pump," explains Dr. Katherine Crothall, CEO of Animas Corporation. "Auto Control's long tenure in the diabetes industry coupled with their reputation for excellent service provides us with a strong presence in Canada and positions us for a highly successful launch of the IR 1200 in Canada."

"The IR 1200 exceptional reputation has preceded its availability in the Canadian marketplace. It is recognized for its unparalleled ease of use, reliability and performance, and we are delighted that it will now be available to our patients," says Grant Reynolds, CEO of Auto Control.

An insulin pump is a pager-sized device that delivers a continuous, variable flow of insulin. Compared to insulin injections, the pump can more precisely match the often-changing insulin requirements of patients. The ability to adjust the amount of insulin by simply pressing a few buttons allows users to live a more active, flexible lifestyle with significant improvement in quality of life and blood glucose control.

IR 1200 launch activities in Canada coincides with launch activities elsewhere in the world. Future plans for international distribution of the IR 1200 include the United Kingdom, Austria, Germany, France, Spain, New Zealand and Australia.

About Animas Corporation: Animas, a leading maker of insulin infusion pumps and related products, is dedicated to improving diabetes management and making insulin pump therapy easier for patients with insulin requiring diabetes and healthcare professionals through product innovation, exemplary customer support and superior customer education. For more information on Animas, visit or call Animas Corporation at 877-937-7867.

Statements in this press release or made by management from time to time regarding Animas Corporation that are not historical facts, are forward-looking statements and are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The following factors, among others, could cause Animas' actual results to differ materially from those described in a forward-looking statement: the technical issues or the failure of the IR 1200 to gain significant market acceptance; failure to capture recurring purchases of ancillary supplies by patients using Animas' pumps; any significant disruption with vendors; any failure to achieve and then maintain profitability; the failure of Animas' ezSet Infusion Set to be fully-developed or commercially accepted; technological breakthroughs in diabetes monitoring, treatment or prevention that could render Animas' products obsolete; failure to comply with any FDA or foreign regulations; an inability to attract and retain personnel; competition; an inability to adequately protect Animas' intellectual property; product liability lawsuits; and the failure to secure or retain third party insurance coverage or reduced reimbursement for Animas' products by third party payors. This list is intended to identify only certain of the principal factors that could cause actual results to differ. Readers are referred to the reports and documents filed from time to time by Animas Corporation with the Securities and Exchange Commission for a discussion of these and other important risk factors. Readers are cautioned not to place undue reliance on forward-looking statements, which are made as of the date of this press release. Animas Corporation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or for any other reason.


Mindy Cooper
Animas Corporation
610-644-8990, ext. 1157

  Home Return to Top

Last Updated: Wednesday November 05, 2014 21:27:24
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2015. Comments and Feedback.